The role of statins in chronic kidney disease

Rajiv Agarwal, Timothy M. Curley

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Chronic kidney disease is associated with cardiovascular event rates that are at least as high as in patients with established atherosclerotic cardiovascular disease or in those with diabetes mellitus. Chronic kidney disease is therefore considered a cardiovascular disease risk equivalent. Treatment of dyslipidemia, which is very common in this population and reflects the pattern seen in the metabolic syndrome, reduces cardiovascular events in patients with chronic kidney disease. Thus, patients with chronic kidney disease should be evaluated and treated for dyslipidemia. Dyslipidemia is a risk factor for the development of impaired kidney function. Dyslipidemia is also associated with progressive renal disease in subjects with no overt renal disease, as well as those with diabetic and nondiabetic kidney disease. Although definitive randomized controlled trials are lacking, the collective evidence suggests that treatment of dyslipidemia is associated with less decline in renal function. The use of potent statins in high doses can lead to transient proteinuria via impairment of proximal tubular receptor-mediated endocytosis, in a dose-dependent manner. Over the long term, however, the use of statins results in a reduction in proteinuria and in the rate of decline of renal function. Several large definitive trials that are currently underway to examine the safety and efficacy of statins in cardiovascular and renal protection should provide more definitive answers on the role of these drugs in this very high risk population.

Original languageEnglish
Pages (from-to)69-81
Number of pages13
JournalAmerican Journal of the Medical Sciences
Volume330
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Chronic Renal Insufficiency
Dyslipidemias
Kidney
Proteinuria
Cardiovascular Diseases
Metabolic Syndrome X
Diabetic Nephropathies
Endocytosis
Population
Diabetes Mellitus
Randomized Controlled Trials
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chronic kidney disease
  • Lipids
  • Proteinuria
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of statins in chronic kidney disease. / Agarwal, Rajiv; Curley, Timothy M.

In: American Journal of the Medical Sciences, Vol. 330, No. 2, 08.2005, p. 69-81.

Research output: Contribution to journalArticle

Agarwal, Rajiv ; Curley, Timothy M. / The role of statins in chronic kidney disease. In: American Journal of the Medical Sciences. 2005 ; Vol. 330, No. 2. pp. 69-81.
@article{3ac03af7295549bb929428aa474af3a0,
title = "The role of statins in chronic kidney disease",
abstract = "Chronic kidney disease is associated with cardiovascular event rates that are at least as high as in patients with established atherosclerotic cardiovascular disease or in those with diabetes mellitus. Chronic kidney disease is therefore considered a cardiovascular disease risk equivalent. Treatment of dyslipidemia, which is very common in this population and reflects the pattern seen in the metabolic syndrome, reduces cardiovascular events in patients with chronic kidney disease. Thus, patients with chronic kidney disease should be evaluated and treated for dyslipidemia. Dyslipidemia is a risk factor for the development of impaired kidney function. Dyslipidemia is also associated with progressive renal disease in subjects with no overt renal disease, as well as those with diabetic and nondiabetic kidney disease. Although definitive randomized controlled trials are lacking, the collective evidence suggests that treatment of dyslipidemia is associated with less decline in renal function. The use of potent statins in high doses can lead to transient proteinuria via impairment of proximal tubular receptor-mediated endocytosis, in a dose-dependent manner. Over the long term, however, the use of statins results in a reduction in proteinuria and in the rate of decline of renal function. Several large definitive trials that are currently underway to examine the safety and efficacy of statins in cardiovascular and renal protection should provide more definitive answers on the role of these drugs in this very high risk population.",
keywords = "Chronic kidney disease, Lipids, Proteinuria, Statins",
author = "Rajiv Agarwal and Curley, {Timothy M.}",
year = "2005",
month = "8",
doi = "10.1097/00000441-200508000-00004",
language = "English",
volume = "330",
pages = "69--81",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The role of statins in chronic kidney disease

AU - Agarwal, Rajiv

AU - Curley, Timothy M.

PY - 2005/8

Y1 - 2005/8

N2 - Chronic kidney disease is associated with cardiovascular event rates that are at least as high as in patients with established atherosclerotic cardiovascular disease or in those with diabetes mellitus. Chronic kidney disease is therefore considered a cardiovascular disease risk equivalent. Treatment of dyslipidemia, which is very common in this population and reflects the pattern seen in the metabolic syndrome, reduces cardiovascular events in patients with chronic kidney disease. Thus, patients with chronic kidney disease should be evaluated and treated for dyslipidemia. Dyslipidemia is a risk factor for the development of impaired kidney function. Dyslipidemia is also associated with progressive renal disease in subjects with no overt renal disease, as well as those with diabetic and nondiabetic kidney disease. Although definitive randomized controlled trials are lacking, the collective evidence suggests that treatment of dyslipidemia is associated with less decline in renal function. The use of potent statins in high doses can lead to transient proteinuria via impairment of proximal tubular receptor-mediated endocytosis, in a dose-dependent manner. Over the long term, however, the use of statins results in a reduction in proteinuria and in the rate of decline of renal function. Several large definitive trials that are currently underway to examine the safety and efficacy of statins in cardiovascular and renal protection should provide more definitive answers on the role of these drugs in this very high risk population.

AB - Chronic kidney disease is associated with cardiovascular event rates that are at least as high as in patients with established atherosclerotic cardiovascular disease or in those with diabetes mellitus. Chronic kidney disease is therefore considered a cardiovascular disease risk equivalent. Treatment of dyslipidemia, which is very common in this population and reflects the pattern seen in the metabolic syndrome, reduces cardiovascular events in patients with chronic kidney disease. Thus, patients with chronic kidney disease should be evaluated and treated for dyslipidemia. Dyslipidemia is a risk factor for the development of impaired kidney function. Dyslipidemia is also associated with progressive renal disease in subjects with no overt renal disease, as well as those with diabetic and nondiabetic kidney disease. Although definitive randomized controlled trials are lacking, the collective evidence suggests that treatment of dyslipidemia is associated with less decline in renal function. The use of potent statins in high doses can lead to transient proteinuria via impairment of proximal tubular receptor-mediated endocytosis, in a dose-dependent manner. Over the long term, however, the use of statins results in a reduction in proteinuria and in the rate of decline of renal function. Several large definitive trials that are currently underway to examine the safety and efficacy of statins in cardiovascular and renal protection should provide more definitive answers on the role of these drugs in this very high risk population.

KW - Chronic kidney disease

KW - Lipids

KW - Proteinuria

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=23744466163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744466163&partnerID=8YFLogxK

U2 - 10.1097/00000441-200508000-00004

DO - 10.1097/00000441-200508000-00004

M3 - Article

C2 - 16103787

AN - SCOPUS:23744466163

VL - 330

SP - 69

EP - 81

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 2

ER -